1. Home
  2. OCSL vs XERS Comparison

OCSL vs XERS Comparison

Compare OCSL & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Oaktree Specialty Lending Corporation

OCSL

Oaktree Specialty Lending Corporation

HOLD

Current Price

$11.85

Market Cap

1.1B

Sector

Finance

ML Signal

HOLD

XERS

Xeris Biopharma Holdings Inc.

HOLD

Current Price

$6.19

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OCSL
XERS
Founded
2007
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.0B
IPO Year
2007
2021

Fundamental Metrics

Financial Performance
Metric
OCSL
XERS
Price
$11.85
$6.19
Analyst Decision
Hold
Buy
Analyst Count
4
6
Target Price
$12.63
$10.83
AVG Volume (30 Days)
742.0K
1.6M
Earning Date
05-05-2026
05-07-2026
Dividend Yield
12.73%
N/A
EPS Growth
N/A
100.00
EPS
N/A
0.01
Revenue
N/A
$49,590,000.00
Revenue This Year
N/A
$34.37
Revenue Next Year
$0.31
$22.86
P/E Ratio
N/A
$623.50
Revenue Growth
N/A
142.67
52 Week Low
$10.63
$4.30
52 Week High
$14.77
$10.08

Technical Indicators

Market Signals
Indicator
OCSL
XERS
Relative Strength Index (RSI) 43.79 49.90
Support Level $11.01 $5.81
Resistance Level $13.89 $6.41
Average True Range (ATR) 0.24 0.31
MACD -0.05 -0.02
Stochastic Oscillator 27.21 30.21

Price Performance

Historical Comparison
OCSL
XERS

About OCSL Oaktree Specialty Lending Corporation

Oaktree Specialty Lending Corp is a specialty finance company. The company provides lending services and invests in small and mid-sized companies. The company's investment objective is to maximize its portfolio's total return by generating current income from debt investments, and to a lesser extent, capital appreciation from equity investments. The company provides customized, one-stop credit solutions to companies with limited access to public or syndicated capital markets. The company operates as a single reportable segment and derives revenues from investing in originated loans and other securities, including broadly syndicated loans, of U.S. private companies and manages the business on a consolidated basis.

About XERS Xeris Biopharma Holdings Inc.

Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.

Share on Social Networks: